HENLIUS (02696) saw its shares rise more than 6% in Hong Kong trading. At the time of writing, the stock was up 5.38%, trading at HK$73.5 with a turnover of HK$88.997 million. The uptick follows an announcement on March 31 that the company has received approval from the National Medical Products Administration (NMPA) for the Investigational New Drug (IND) application for its self-developed HLXTEHAase02, a recombinant human hyaluronidase injection. The company plans to initiate a Phase 1 clinical trial in mainland China once conditions are met. HLXTEHAase02 is a novel recombinant human hyaluronidase (rHuPH20) developed by HENLIUS, intended to enhance the diffusion and absorption of subcutaneously injected or infused drugs. Under physiological conditions, HLXTEHAase02 can locally and reversibly break down hyaluronic acid in subcutaneous tissue, allowing for larger injection volumes and improving the dispersion and permeability of drugs. This leads to increased drug bioavailability and better patient compliance with subcutaneous administration. The product is designed for use in developing subcutaneous drug delivery systems to enable more effective subcutaneous administration. Non-clinical studies indicate that HLXTEHAase02 demonstrates enzyme activity comparable to currently marketed recombinant human hyaluronidase products.
Comments